Profile - To The Moon

Ohm

Posts · 2Posts · 2
Following · 0Following · 0
Followers · 0Followers · 0

- OhmOhm
  ·2022-01-17
  Good
  2 Top Biotech Stocks to Buy and Hold for 10 Years
  Both companies are involved in the fight against COVID-19.
  2 Top Biotech Stocks to Buy and Hold for 10 Years
  2.10K Comment
  5
  Share
  Report
- OhmOhm
  ·2022-01-17
  Hi
  AMC’s Business Strategy Remains Flawed, Hurting AMC Stock
  A flawed business strategy suggests AMC stock ought to be trading in the teens
  AMC’s Business Strategy Remains Flawed, Hurting AMC Stock
  2.04K Comment
  6
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4100492316089130","uuid":"4100492316089130","gmtCreate":1637394747686,"gmtModify":1637394747686,"name":"Ohm","pinyin":"ohm","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9005728315,"gmtCreate":1642419882262,"gmtModify":1676533709254,"author":{"id":"4100492316089130","authorId":"4100492316089130","name":"Ohm","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100492316089130","authorIdStr":"4100492316089130"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005728315","repostId":"2204773593","repostType":4,"repost":{"id":"2204773593","kind":"highlight","pubTimestamp":1642419504,"share":"https://ttm.financial/m/news/2204773593?lang=en_US&edition=fundamental","pubTime":"2022-01-17 19:38","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy and Hold for 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2204773593","media":"Motley Fool","summary":"Both companies are involved in the fight against COVID-19.","content":"<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy and Hold for 10 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy and Hold for 10 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","BK4551":"寇图资本持仓","BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4139":"生物科技","REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2022/01/17/2-top-biotech-stocks-to-buy-and-hold-for-10-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204773593","content_text":"Time is one of an investor's greatest weapons. While there is no telling how the stock market will behave on a particular day or week, those companies that consistently produce outstanding financial results will typically be rewarded in the long term, along with their shareholders.That's why it's essential to ignore short-term volatility and instead focus on companies' long-term prospects. With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna  and Regeneron .MRNA data by YCharts1. Moderna Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market. The final numbers aren't in yet, but Moderna said it expects sales of mRNA-1273 to land between $15 billion and $18 billion for the fiscal year 2021.As of Sept. 30, the company had recorded $11.3 billion in total revenue and $7.3 billion in net income. The company has already signed about $17 billion worth of advanced purchase agreements for mRNA-1273 for 2022, and it thinks it could generate revenue between $17 billion and $22 billion for the year.Moderna won't let all this money go to waste, and it is advancing several exciting candidates. The company's pipeline features other vaccines targeting newer variants of the coronavirus, a combined flu and COVID-19 vaccine, and vaccines against viruses for which there are currently none, including the Zika virus and the cytomegalovirus.That's not all. Last year, management expressed its desire to jump into the promising gene-editing space. The company is looking to set up license agreements with gene-editing companies, and perhaps it could even acquire a smaller biotech that focuses on gene editing. With $15.3 billion in cash and cash equivalents as of Sept. 30, Moderna has a lot of flexibility to expand its already-exciting pipeline.Although Moderna's shares skyrocketed in the past couple of years, it remains reasonably valued, at least when going by traditional valuation metrics. The company's forward price to earnings (P/E) ratio of 7.9 looks a lot better than the biotech's industry average of 11.2.While the company's stock may see tougher times once its coronavirus tailwind ends -- which won't happen anytime soon -- Moderna's long-term prospects look bright.2. Regeneron Regeneron is yet another company benefiting from its coronavirus-related work. In the third quarter, the biotech's revenue increased by 51% year over year to $3.4 billion. The company had its antibody cocktail for the treatment and prevention of COVID-19, REGEN-COV, to thank for this performance. Sales of this product came in at $804 million for the quarter.Regeneron will continue to benefit from this tailwind, at least for a bit longer. True, there is now more competition in the market for COVID-19 therapies; both Merck and Pfizer recently earned authorization for their respective products in this space.However, given the recent surge in cases, combined with the fact that REGEN-COV recently earned approval in the European Union, sales of the coronavirus therapy won't drop off a cliff. Indeed, management has high hopes for the product.To quote Regeneron's CEO, Leonard Schleifer: \"Given the anticipation of new COVID infections over time, increased utilization of REGEN-COV in appropriate cases and the need for prophylaxis in immunocompromised individuals, we anticipate an ongoing role for REGEN-COV.\"But Regeneron isn't just a coronavirus play. In Q3, the company's revenue excluding REGEN-COV came in at $2.6 billion, 15.3% higher than the year-ago period.For a biotech company of this size, that's still an excellent performance. Products such as Eylea, which treats a chronic eye disorder called wet age-related macular degeneration, continue to perform well. Regeneron markets Eylea in the U.S., while Bayer markets it outside the U.S. The two entities share the profits and losses associated with the medicine in international markets.Regeneron's sales of Eylea in Q3 increased by 12% to $1.5 billion. Add that to other medicines, including Dupixent and Libtayo, not to mention the more than 30 clinical programs the company boasts (including 10 in phase 3 studies), Regeneron's future looks great. With a reasonable forward P/E of 12.8, now is as good a time as any to add shares of this biotech stock to your portfolio.","news_type":1,"symbols_score_info":{"BNTX":0.82,"REGN":1,"MRNA":1}},"isVote":1,"tweetType":1,"viewCount":2099,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005721429,"gmtCreate":1642419711492,"gmtModify":1676533709262,"author":{"id":"4100492316089130","authorId":"4100492316089130","name":"Ohm","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100492316089130","authorIdStr":"4100492316089130"},"themes":[],"htmlText":"Hi&nbsp;","listText":"Hi&nbsp;","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005721429","repostId":"1130015249","repostType":4,"repost":{"id":"1130015249","kind":"news","pubTimestamp":1642419660,"share":"https://ttm.financial/m/news/1130015249?lang=en_US&edition=fundamental","pubTime":"2022-01-17 19:41","market":"us","language":"en","title":"AMC’s Business Strategy Remains Flawed, Hurting AMC Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1130015249","media":"InvestorPlace","summary":"A flawed business strategy suggests AMC stock ought to be trading in the teens","content":"<div>\n<p>AMC Entertainment(NYSE:AMC) continues its strategic expansion of U.S. theater locations. While that might give it a greater market share, it’s a terrible move for shareholders and AMC stock.On Dec. 22...</p>\n\n<a href=\"https://investorplace.com/2022/01/amcs-business-strategy-remains-flawed-hurting-amc-stock/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC’s Business Strategy Remains Flawed, Hurting AMC Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC’s Business Strategy Remains Flawed, Hurting AMC Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/01/amcs-business-strategy-remains-flawed-hurting-amc-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AMC Entertainment(NYSE:AMC) continues its strategic expansion of U.S. theater locations. While that might give it a greater market share, it’s a terrible move for shareholders and AMC stock.On Dec. 22...</p>\n\n<a href=\"https://investorplace.com/2022/01/amcs-business-strategy-remains-flawed-hurting-amc-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://investorplace.com/2022/01/amcs-business-strategy-remains-flawed-hurting-amc-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130015249","content_text":"AMC Entertainment(NYSE:AMC) continues its strategic expansion of U.S. theater locations. While that might give it a greater market share, it’s a terrible move for shareholders and AMC stock.On Dec. 22, AMC announced that it had reached lease agreements for former Pacific Theatres and ArcLight Cinemas locations in Los Angeles and Chicago. Additionally, in 2021, it acquired four theater locations from the now-defunct theater chain. The theaters are expected to reopen under the AMC banner this spring.AMC CEO Adam Aron was pumped about the theater acquisitions:“These theat[er]s have previously been high-traffic, successful locations, in two of AMC’s top markets, and we are pleased to offer the AMC experience at them a few months from now in 2022,” Aron stated in the company’s December press release.“These are prime examples of how AMC is staying on offense, looking for opportunities to strengthen our company through the acquisition of these popular locations.”The CEO went on to say that amongst the approximately 150 theaters in the Los Angeles area, two recent acquisitions in Southern California – AMC The Grove 14 and AMC American at Brand 18 – are routinely in the top 10 for box office receipts in the region.According to the company website, there are 38 theaters in the Los Angeles area. The 2020 10-K says California had 54 theaters at the end of 2020. So, the LA market accounts for almost three-quarters of its California business. Based on597 theatersin the U.S. as of the end of September, the LA market accounts for 6% of its total theater count.So, you could look at the numbers above and surmise that the company has plenty of expansion possibilities in the LA market, or you could view its 25% market share in LA as plenty, given AMC already controls a majority of theaters across the country.Does it need more than 600 theaters in the U.S.?What’s the Los Angeles Market Worth?An article from the Los Angeles Times says that city is“the nation’s biggest box office market,”but it doesn’t provide any specifics. However, the March 2021 article did say that the U.S. box office revenue in 2019 was $11.3 billion.According toCNBCdata from Comscore, Los Angeles is the largest designated market area (DMA) in the U.S., accounting for 8.9% of ticket sales, 150 basis points ahead of New York.So, Los Angeles’s share of 2019’s box office was approximately $1 billion [$11.3 billion x 8.9%]. Based on my guesstimate of 25% market share in the Los Angeles DMA, it’s worth $250 million in revenue to AMC stock each year.In 2019, AMC’s revenue from admissions was $3.3 billion, which suggests Los Angeles accounted for approximately 7.6% of its overall box office. Using the same assumption, food and beverage were worth an additional $130.7 million in revenue [$1.72 billion x 7.6%]  in the Los Angeles market. That’s $380.7 million in total.Based on a current price-sales ratio of 5.8x, my back-of-the-napkin estimate suggests Los Angeles is worth $2.2 billion in market capitalization.However, that assumes that the P/S multiple is reasonable. In 2019, its P/S ratio was o.2x. At this multiple, Los Angeles is worth $76.1 million, not $2.2 billion.The Bottom Line on AMC StockIn the end, AMC’s reliance on movies and theaters will be its undoing. The country doesn’t need more theaters. According to Page 12 of its 2019 10-K, there were 5,548 theaters in the U.S. and Canada. Back out the standard 10% for Canada – Canada’s population is approximately 10% of the U.S. – and you have 4,993 in America. AMC’s 597  theaters account for about 12% overall.You can add more theaters and screens to bump up the 12%, but ultimately, the trend in terms of attendance is declining.To deserve its $11.7 billion market cap, AMC has got to bring to the table a more diversified set of revenue streams. But, unfortunately, higher ticket and food/beverage prices can only do so much.As the business is constructed today, I’m not sure how any investor can view its potential growth with anything but skepticism.Its business strategy remains flawed.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}